Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

• William L Redmond,
• Annah S Rolig,
• Daniel C Rose,
• Saul Kivimae,
• Werner Rubas,
• Grace Helen McGee

Affiliations

William L Redmond

Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA

Annah S Rolig

Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA

Daniel C Rose

Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA

Saul Kivimae

Research Biology: Pharmacology, Nektar Therapeutics, San Francisco, California, USA

Werner Rubas

Research Biology: Pharmacology, Nektar Therapeutics, San Francisco, California, USA

Grace Helen McGee

Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA